Study finds weight loss drug effective for diabetes remission

Weight loss also led to induced remission of high blood sugar among diabetics and reduced the risk of diabetic microvascular complications such as microalbuminuria, a moderate increase in the level of urine albumin.

A new study has found that a weight-loss drug, lorcaserin, can help decrease risk for diabetes, induce diabetes remission as well as reduce the risk of diabetes complications in obese and overweight patients. According to the Financial Express report, the researchers from the Brigham and Women s Hospital (BWH) found that lorcaserin reduced the risk of diabetes by 19 per cent in patients with pre-diabetes, diabetic neuropathy (a type of nerve damage that can occur with diabetes by 21 per cent).

It also led to induced remission of high blood sugar among diabetics and reduced the risk of diabetic microvascular complications such as microalbuminuria, a moderate increase in the level of urine albumin.

Erin Bohula from the BWH reportedly said that earlier the researchers found that the use of lorcaserin resulted in modest but sustained weight loss among obese and overweight patients without increasing risk of heart attack and stroke.

Reportedly, Bohula also said that wow they report that, when added to lifestyle interventions, lorcaserin significantly reduced the incidence of diabetes, increased rates of diabetes remission, and reduced the risk of diabetic microvascular complications.

The study has been published in the journal The Lancet. The team randomly assigned 12,000 overweight or obese patients at risk for a cardiovascular event were to receive either lorcaserin or a placebo.

The results showed that 9.5 per cent of patients were able to achieve normal glycemic levels.

Lorcaserin also significantly increased the rate of remission of hyperglycemia in patients with diabetes, with 7.1 per cent of patients on the drug achieving remission compared to 6 per cent of patients on the placebo.

Lorcaserin also helped patients lower their weight by 4.2 kilograms (9.3 pounds) on average compared to 1.4 kg for placebo at one year.

Benjamin Scirica, from the hospital, reportedly said that these findings reinforce the notion that modest, durable weight loss can improve cardiometabolic health and supports the role of lorcaserin as an adjunctive therapy in chronic weight management.